Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus

International Reviews of Immunology

Volumn 33, Issue 4, 2014, Pages 330-363

  Caza, Tiffany ^a   Oaks, Zachary ^a   Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Autophagy; Bystander activation; Endogenous retrovirus; Immunosuppression; Infections; Molecular mimicry; Systemic lupus erythematosus; Vaccinations

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HEPATITIS B VACCINE; HYDROXYCHLOROQUINE SULFATE; INFLUENZA VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; RAPAMYCIN; RITUXIMAB; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; ANTIOXIDANT; VACCINE;

ABSENCE OF SIDE EFFECTS; ACINETOBACTER INFECTION; ANTIBIOTIC THERAPY; ASPERGILLUS FUMIGATUS; AUTOIMMUNITY; BACTERIAL INFECTION; BORRELIA BURGDORFERI; CANDIDA ALBICANS; COCCIDIOIDES IMMITIS; CORTICOSTEROID THERAPY; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; ENDOGENOUS RETROVIRUS; ENTEROCOCCUS; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; ESCHERICHIA COLI; FASCIOLA HEPATICA; HELICOBACTER PYLORI; HELIGMOSOMOIDES POLYGYRUS; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PARVOVIRUS B19; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LEISHMANIA; LISTERIA MONOCYTOGENES; LITOMOSOIDES SIGMODONTIS; MOLECULAR MIMICRY; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOBACTERIUM; MYCOSIS; NEISSERIA; NOCARDIA; ONCOVIRINAE; OPPORTUNISTIC INFECTION; PAPILLOMATOSIS; PARAMYXOVIRUS; PARASITOSIS; PATHOGEN CLEARANCE; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; REVIEW; SALMONELLA; SCHISTOSOMA MANSONI; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; STRONGYLOIDES STERCORALIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TORQUE TENO VIRUS; TOXOPLASMA GONDII; TREATMENT RESPONSE; TRICHINELLA SPIRALIS; TYPHOID FEVER; VACCINATION; VACCINE FAILURE; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WART VIRUS; ANTIBIOTIC PROPHYLAXIS; COMPLICATION; FEMALE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROCEDURES;

ANTIBIOTIC PROPHYLAXIS; ANTIOXIDANTS; AUTOIMMUNITY; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; VACCINES;

EID: 84903755667     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.863305     Document Type: Review

References (277)

1. Perl A. Systems biology of lupus:mapping the impact of genomic andenvironmental factorsongene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity 2010;43:32-47.
2. Alarcón-Segovia D, Alarcón-Riquelme ME,Cardiel MH,et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 2005;52:1138-1147. (Pubitemid 40530121)
3. Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 2013;41:25-33.
4. Crispín JC, Hedrich CM, Tsokos GC. Gene-function studies in systemic lupus erythematosus. Nat Rev Rheumatol 2013;9:476-484.
5. Getts MT,Miller SD. 99th dahlem conference on infection, inflammation and chronicinflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol 2010;160:15-21.
6. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996;25:318-336. (Pubitemid 26123844)
7. Rovin BH, Tang Y, Sun J, et al. Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. Kidney Int 2005;68:747-759. (Pubitemid 43323130)
8. Francis L, Perl A. Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumatol 2010;5:59-74.
9. Dias AMB,Do Couto MCM,Duarte CCM, et al. White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE. Ann NY Acad Sci 2009;1173:103-107.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
11. Scarisbrick IA, RodriguezM. Hit-Hit and Hit-Run: viruses in the playing field of multiple sclerosis. Curr Neurol Neurosci Rep 2003;3:265-271. (Pubitemid 38899011)
12. Zonana-Nacach A,Camargo-Coronel A, Yãnez P, et al. Infections in outpatientswith systemic lupus erythematosus: a prospective study. Lupus 2001;10:505-510. (Pubitemid 32675052)
13. Yang C, Wang X, Ye S, et al. Clinical features, prognostic and risk factors of central nervous system infections in patients with systemic lupus erythematosus. Clin Rheumatol 2007;26:895-901. (Pubitemid 46951285)
14. Jeong SJ, Choi H, LeeHS, et al. Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 2009;41:268-274.
15. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis ResTher 2009:11.
16. Chen M, Tseng H, Huang Y, et al. Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology 2008;47:1352-1357.
17. Han BK, Bhatia R, Traisak P, et al. Clinical presentations and outcomes of systemic lupus erythematosus patients with infection admitted to the intensive care unit. Lupus 2013;22:690-696.
18. Wu S, Yeh K, Lee W, et al. Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus. Lupus 2013;22:279-288.
19. Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol 2003;25:29-39. (Pubitemid 36819442)
20. Feng P, Lin S Yu C, et al. Inadequate antimicrobial treatment for nosocomial infection is amortality risk factor for systemic lupus erythematous patients admitted to intensive care unit. Am J Med Sci 2010;340:64-68.
21. Davies EJ, Snowden N, Hillarby MC, et al. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995;38:110-114.
22. TrendelenburgM. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 2005;27:276-285. (Pubitemid 41639881)
23. Agnello V. Lupus diseases associated with hereditary and acquired deficiencies of complement. Springer Semin Immunopathol 1986;9:161-178.
24. Lockshin MD, Qamar T, Redecha P, Harpel PC. Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus. Arthritis Rheum 1986;29:1467-1472. (Pubitemid 17003884)
25. Sliwinski AJ, Zvaifler NJ. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol 1972;11:21-29.
26. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J ExpMed 1982;155:1427-1438. (Pubitemid 12102088)
27. Neilan BA, Berney SN. Hyposplenism in systemic lupus erythematosus. J Rheumatol 1983;10:332-334. (Pubitemid 13064196)
28. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528-534. (Pubitemid 37041388)
29. De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008;122:1097-1103.
30. Campbell AM, Kashgarian M, Shlomchik MJ. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Trans Med 2012:4.
31. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011;7:691-699.
32. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nature Rev Immunol 2006;6:823-835. (Pubitemid 44631651)
33. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-a/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-243. (Pubitemid 33704208)
34. Rönnblom L, Alm GV. A pivotal role for the natural interferon a-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J ExpMed 2001;194:F59-F63. (Pubitemid 34028649)
35. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011:3. doi: 10. 1126/scitranslmed. 3001180.
36. Kadowaki N, Liu Y. Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum Immunol 2002;63:1126-1132. (Pubitemid 36025987)
37. Garcia-Romo GS, et al. Netting neutrophils aremajor inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci TranslMed 2011:3. doi: 10. 1126/scitranslmed. 3001201.
38. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-a in systemic lupus erythematosus. Science 2001;294:1540-1543. (Pubitemid 33063928)
39. Bennett L, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J ExpMed 2003;197:711-723. (Pubitemid 36350866)
40. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-2962. (Pubitemid 44497776)
41. Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 2003;12:222-230. (Pubitemid 36458681)
42. Sigurdsson S, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. HumMol Genet 2008;17:872-881. (Pubitemid 351368993)
43. Hakkim A, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010;107:9813-9818.
44. Brinkmann V, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-1535. (Pubitemid 38314426)
45. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981;1:55-60. (Pubitemid 11038705)
46. Leffler J, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012;188:3522-3531.
47. Knight JS, Carmona-Rivera C, KaplanMJ. Proteins derived fromneutrophil extracellular trapsmay serve as self-antigens and mediate organ damage in autoimmune diseases. Frontiers Immunol 2012;3. doi: 10. 3389/fimmu. 2012. 00380.
48. Tillack K, Breiden P,Martin R, SospedraM. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol 2012;188:3150-3159.
49. Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 2005;25:123-140. (Pubitemid 40910585)
50. Lai Z, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum 2012;n/a-n/a.
51. Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Panomvana Na, Ayudhya D. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J Clin Pharm Ther 2010;35:483-485.
52. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012;189:2689-2695.
53. Kawai T, Akira S. Toll-like receptor and RIG-1-like receptor signaling. Ann NY Acad Sci 2008;1143:1-20.
54. Correa RG,Milutinovic S, Reed JC. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci Rep 2012;32:597-608.
55. Pothlichet J, Niewold TB, Vitour D, et al. A loss-of-function variant of the antiviralmoleculeMAVS is associated with a subset of systemic lupus patients. EMBOMolMed 2011;3:142-152.
56. Loo Y, Fornek J, Crochet N, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 2008;82:335-345. (Pubitemid 350309149)
57. Perl A, Fernandez DR, Telarico T, et al. T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol 2009;21:454-464.
58. Iwata Y,Matsushita T, HorikawaM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117:530-541.
59. Stohl W, Hamilton AS, Deapen DM, et al. Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells. Lupus 1999;8:293-299. (Pubitemid 29292094)
60. Puliaeva I, Puliaev R, Via CS. Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun Rev 2009;8:219-223.
61. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116:1218-1222.
62. Kammer GM. Altered regulation of IL-2 production in systemic lupus erythematosus: an evolving paradigm. J Clin Invest 2005;115:836-840. (Pubitemid 40489386)
63. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178:2579-2588. (Pubitemid 46233461)
64. FernandezDR, Telarico T, Bonilla E, et al. Activation ofmammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (Baltimore,MD: 1950) 2009;182:2063-2073.
65. Delgoffe GM, Kole TP, Zheng Y, et al. ThemTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009;30:832-844.
66. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 andmTORC2. Nat Immunol 2011;12:295-304.
67. Cunningham JT, Rodgers JT, Arlow DH, et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1 transcriptional complex. Nature 2007;450:736-740. (Pubitemid 350207689)
68. Kim J, Kundu M, Viollet B,Guan KL. AMPKandmTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-141.
69. Koren I, Reem E, Kimchi A. DAP1, a novel substrate ofmTOR, negatively regulates autophagy. Curr Biol 2010;20:1093-1098.
70. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Ann Rev Immunol 2012;30:611-646.
71. Shen S, Niso-Santano M, Adjemian S, et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell 2012;48:667-680.
72. Gros F, Arnold J, Page N, et al. Macroautophagy is deregulated inmurine and human lupus T lymphocytes. Autophagy 2012;8(7):1113-1123.
73. Alessandri C, Barbati C, Vacirca D, et al. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J 2012;26:4722-4732.
74. Zhou X, et al. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann Rheum Dis 2011;70:1330-1337.
75. Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patientswith systemic lupus erythematosus. Arthritis Rheum 2006;54:2983-2988. (Pubitemid 44497779)
76. Caza TN, Talaber G, Perl A. Metabolic regulation of organelle homeostasis in lupus T cells. Clin Immunol 2012;144:200-213.
77. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92:211-218. (Pubitemid 29184885)
78. Francis L, Perl A. Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother 2009;10:1481-1494.
79. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
80. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-2089.
81. Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Care Res 2008;59:1796-1804.
82. Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-termrenal outcome. Clin J AmSoc Nephrol 2009;4:579-587.
83. Mosca M, Tani C, Carli L, Bombardieri S. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011;29:S126-S129.
84. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003;362:1828-1838. (Pubitemid 37494764)
85. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-963.
86. Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308-312. (Pubitemid 46579629)
87. Martínez-Martínez MU,Herrera-Van Oostdam D, Román-Acosta S, et al. Invasive fungal infections in patients with systemic lupus erythematosus. J Rheumatol 2012;39:1814-1818.
88. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, et al. Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol 2008;26:S67-S73. (Pubitemid 351578098)
89. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001;15:423-432. (Pubitemid 32606908)
90. Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:823-830. (Pubitemid 28225782)
91. McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-1431.
92. Ginzler EM,Dooley MA, AranowC, et al. Mycophenolatemofetil or intravenous cyclophosphamide for lupus nephritis. N Engl JMed 2005;353:2219-2228. (Pubitemid 41697285)
93. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996;39:1475-1482. (Pubitemid 26314980)
94. Borba EF, Ribeiro ACM, Martin P, et al. Incidence, risk factors, and outcome of herpes zoster in systemic lupus erythematosus. J Clin Rheumatol 2010;16:119-122.
95. Andrew RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies ofmycophenolatemofetil in lupus nephritis. Arthritis ResTher 2006:8.
96. Gaubitz M, Schorat A, Schotte H, et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731-736.
97. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-742. (Pubitemid 44215349)
98. Arends S, Grootscholten C,Derksen RHWM, et al. Long-termfollow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 2012;71:966-973.
99. Ginzler E, DiamondH, KaplanD, et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978;21:37-44. (Pubitemid 9127950)
100. Wong JM, Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus 2005;14:101-105. (Pubitemid 40327659)
101. Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Care Res 2008;59:1796-1804.
102. Boerbooms AMT, Kerstens PJSM, Van Loenhout JWA, et al. Infections during low-dosemethotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-421.
103. Shprecher D, Frech T, Chin S, et al. Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus 2008;17:1029-1032.
104. Ramos-Casals M, SotoMJ, CuadradoMJ, Khamashta MA. Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases. Lupus 2009;18:767-776.
105. Armstrong D, Wright S, McVeigh C, Finch M. Infective endocarditis complicating rituximab (anti- CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis? Clin Rheumatol 2006;25:583-584. (Pubitemid 44137648)
106. Tsai M, Chou C, Lin F, Chang S. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus 2012;21:914-918.
107. Gerona JG,Navarra SV. Salmonella infections in patientswith systemic lupus erythematosus: a case series. Int J Rheum Dis 2009;12:319-323.
108. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-3930.
109. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet 2011;377:721-731.
110. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl JMed 2013;368:1528-1535.
111. Terada N, Lucas JJ, Szepesi A, et al. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun 1992;186:1315-1321. (Pubitemid 23189467)
112. Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 1994;156:493-507. (Pubitemid 24252902)
113. Fernandez D, Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? DiscovMed 2010;9:173-178.
114. Nagy G, Koncz A, Fernandez D, Perl A. Nitric oxide, mitochondrial hyperpolarization, and T cell activation. Free Radic BiolMed 2007;42:1625-1631. (Pubitemid 46629013)
115. Riise GC, Larsson S, Larsson P, et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J 1994;7:94-101. (Pubitemid 24075131)
116. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and Nacetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother 2007;51:1556-1558. (Pubitemid 46586852)
117. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell- mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997;10:1535-1541. (Pubitemid 27311068)
118. Roederer M, Staal FJT, Ela SW, et al. N-Acetylcysteine: potential for AIDS therapy. Pharmacology 1993;46:121-129. (Pubitemid 23052784)
119. Tugnet N, Rylance P, Roden D, et al. Human Endogenous Retroviruses (HERVs) and autoimmune rheumatic disease: is there a link? The Open Rheumatol J 2013;7:13-21.
120. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J ExpMed 2005;201:703-711. (Pubitemid 40395116)
121. Samuels J, Ng Y, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J ExpMed 2005;201:1659-1667. (Pubitemid 40721009)
122. Lovett-Racke AE, Trotter JL, Lauber J, et al. Decreased dependence of myelin basic proteinreactive T cells on CD28- mediated costimulation in multiple sclerosis patients: a marker of activated/ memory T cells. J Clin Invest 1998;101:725-730. (Pubitemid 28096067)
123. Deng G, Tsokos GC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol 2008;181:4019-4026.
124. Dennig D, Yan Y, Ferguson K, O'Reilly RJ. A novel HLA class II-independent TCR-mediated T cell activationmechanism is distinguished by theV specificity of the proliferating oligoclones and their capacity to generate interleukin-2. Cell Immunol 1996;171:200-210. (Pubitemid 26268475)
125. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-157.
126. Witt MN, Braun GS, Ihrler S, SchmidH. Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease. BMC PulmMed 2009:9. doi: 10. 1186/1471-2466-9-22.
127. Zhang L, Liu J, Li M. Herpes simplex virus type 1 encephalitis and unusual retinitis in a patient with systemic lupus erythematosus. Lupus 2013;22(13):1403-1408.
128. Catoggio C, Alvarez-Uría A, Fernandez PL, et al. Catastrophic antiphospholipid syndrome triggered by fulminant disseminated herpes simplex infection in a patient with systemic lupus erythematosus. Lupus 2012;21:1359-1361.
129. Wakui H, Togashi M, Omokawa A, et al. Simultaneous herpes simplex virus esophagitis and lupus enteritis in a patient with systemic lupus erythematosus. Mod Rheumatol 2010;20:98-101.
130. Cogman AR, Chakravarty EF. The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine 2013;31:3640-3643.
131. Park H, KimK, Park J, et al. Association of reduced CD4 T cell responses specific to varicella zoster viruswithhighincidence of herpes zoster in patientswith systemic lupus erythematosus. JRheumatol 2004;31:2151-2155. (Pubitemid 39453233)
132. McClain MT, Heinlen LD, Dennis GJ, et al. Early events in lupus humoral autoimmunity suggest initiation through molecularmimicry. NatMed 2005;11:85-89. (Pubitemid 40215842)
133. Rosén A, Gergely P, Jondal M, et al. Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro 16 Nature 1977;267:52-54.
134. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998;9:395-404. (Pubitemid 28462760)
135. McClainMT, Poole BD, Bruner BF, et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006;54:360-368. (Pubitemid 43122221)
136. Arbuckle MR,Gross T, Scofield RH, et al. Lupus humoral autoimmunity induced in a primate model by short peptide immunization. J InvestMed 1998;46:58-65. (Pubitemid 128452770)
137. Sundar K, Jacques S,Gottlieb P, et al. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA- 1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun 2004;23:127-140. (Pubitemid 39485794)
138. Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012:2012.
139. James JA, Neas BR,Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-1126. (Pubitemid 32433618)
140. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-3026. (Pubitemid 28022839)
141. Larsen M, Sauce D, Deback C, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathogens 2011:7.
142. Gross AJ, Hochberg D, Rand WM,Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005;174:6599-6607. (Pubitemid 40705620)
143. Moon UY, Park SJ, Oh ST, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis ResTher 2004;6:R295-302.
144. Yokochi T, Yanagawa A, Kimura Y, Mizushima Y. High titer of antibody to the Epstein-Barr virus membrane antigen in sera frompatientswith rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1989;16:1029-1032. (Pubitemid 19234727)
145. Cunha BA, Gouzhva O, Nausheen S. Severe cytomegalovirus (CMV) community-acquired pneumonia (CAP) precipitating a systemic lupus erythematosus (SLE) flare. Heart Lung: J Acute Critical Care 2009;38:249-252.
146. Su BY, Su C, Yu S, Chen C. Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity. Med Microbiol Immunol (Berl. ) 2007;196:165-170. (Pubitemid 47300254)
147. Varani S, et al. High TNF-alpha and IL-8 levels predict low blood dendritic cell counts in primary cytomegalovirus infection. J Clin Virol 2012;53:360-363.
148. Yoon KH, FongKY, Tambyah PA. Fatal cytomegalovirus infection in two patientswith systemic lupus erythematosus undergoing intensive immunosuppressive therapy: role for cytomegalovirus vigilance and prophylaxis? J Clin Rheumatol 2002;8:217-222. (Pubitemid 34879363)
149. Sun Y, Sun S, Li W, et al. Prevalence of human herpesvirus 8 infection in systemic lupus erythematosus. Virol J 2011:8.
150. Geraminejad P, Memar O, Aronson I, et al. Kaposi's sarcoma and other manifestations of human herpesvirus 8. J Am Acad Dermatol 2002;47:641-655. (Pubitemid 35239323)
151. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010;10:707-719.
152. Chatterjee M, Osborne J, Bestetti G, et al. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 2002;298:1432-1435. (Pubitemid 35346145)
153. Tackey E, Lipsky PE, IlleiGG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-343. (Pubitemid 38788493)
154. Gergely Jr. P, Pullmann R, Stancato C, et al. Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol 2005;116:124-134. (Pubitemid 40910238)
155. Cope AP, Jones A, Brozovic M, et al. Possible induction of systemic lupus erythematosus by human parvovirus. Ann Rheum Dis 1992;51:803-804.
156. Trapani S, Ermini M, Falcini F. HumanparvovirusB19 infection: its relationshipwith systemic lupus erythematosus. Semin Arthritis Rheum 1999;28:319-325. (Pubitemid 29211375)
157. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003;70:6-11. (Pubitemid 36350406)
158. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013:1-7.
159. Tam L, Chan AYK, Chan PKS, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004;50:3619-3625. (Pubitemid 39488689)
160. Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 1996;56:3967-3974. (Pubitemid 26284746)
161. Ramos-Casals M, Font J, García-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 2000;43:2801-2806. (Pubitemid 32001747)
162. Cacoub P, Renou C, Rosenthal E, et al. Extrahepaticmanifestations associatedwith hepatitis C virus infection: a prospectivemulticenter study of 321 patients. Medicine 2000;79:47-56. (Pubitemid 30077736)
163. Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006;27: 134-139. (Pubitemid 44528263)
164. Wahid Fadilah S, Norella K, Shahril M, et al. The development of systemic lupus erythematosus following interferon-a therapy for hepatitis C infection. APLAR J Rheumatol 2006;9:286-289. (Pubitemid 44473302)
165. Phillips PE, Christian CL. Myxovirus antibody increases in human connective tissue disease. Science 1970;168:982-984.
166. Wolf RE, Ziff M. Lymphocyte response to virus antigens in systemic lupus erythematosus. Arthritis Rheum 1976;19:1271-1277.
167. Perl A, FernandezD, Telarico T, Phillips PE. Endogenous retroviral pathogenesis inlupus. CurrOpin Rheumatol 2010;22:483-492.
168. Bailer RT, Lazo A,Harisdangkul V, et al. Lack of evidence for human T
169. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4+CD25+ regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004;126:81-84. (Pubitemid 38859486)
170. Pullmann Jr. R, Bonilla E, Phillips PE, et al. Haplotypes of the HRES-1 endogenous retrovirus are associatedwith development anddiseasemanifestations of systemic lupus erythematosus. Arthritis Rheum 2008;58:532-540. (Pubitemid 351294887)
171. Barthel HR, Wallace DJ. False-positive human immunodeficiency virus testing in patients with lupus erythematosus. Semin Arthritis Rheum 1993;23:1-7. (Pubitemid 23270888)
172. Furie RA. Effects of human immunodeficiency virus infection on the expression of rheumatic illness. Rheum Dis Cli North Am 1991;17:177-188.
173. Drake WP, Byrd VM, Olsen NJ. Reactivation of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for acquired immunodeficiency syndrome. J Clin Rheumatol 2003;9:176-180. (Pubitemid 37465876)
174. Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002;81:213-227. (Pubitemid 34507208)
175. Crispín JC,KyttarisVC,Terhorst C,TsokosGC. Tcells as therapeutic targets inSLE. Nat RevRheumatol 2010;6:317-325.
176. Barblu L, MacHmach K, Gras C, et al. Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-and differentiate into functional killer pDCs under HIV activation. J Infect Dis 2012;206:790-801.
177. Carugati M, Franzetti M, Torre A, et al. Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. Clin Rheumatol 2013:1-7.
178. Hazarika I, Chakravarty BP, Dutta S, Mahanta N. Emergence of manifestations of HIV infection in a case of systemic lupus erythematosus following treatment with IV cyclophosphamide. Clin Rheumatol 2006;25:98-100.
179. Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev 2013;254:78-101.
180. King MR, Ismail AS, Davis LS, Karp DR. Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype. J Immunol 2006;176:2765-2772.
181. Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV Study. J Acquir Immune Defic Syndr 2008;48:272-280.
182. Hsiao FC, Lin M, Tai A, et al. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J Immunol 2006;177:2056-2060. (Pubitemid 44200962)
183. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009;18:1136-1143.
184. Krieg AM, Gourley MF, Perl A. Endogenous retroviruses: potential etiologic agents in autoimmunity. FASEB J 1992;6:2537-2544.
185. Chu J, Drappa J, Parnassa A, Elkon KB. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J ExpMed 1993;178:723-730. (Pubitemid 23218222)
186. Yang Y, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007;131:873-886. (Pubitemid 350138088)
187. Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III) 35 DNA exonuclease develop inflammatorymyocarditis. Mol Cell Biol 2004;24:6719-6727. (Pubitemid 38944351)
188. Lee-Kirsch MA, Chowdhury D, Harvey S, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. JMolMed 2007;85:531-537. (Pubitemid 46701663)
189. Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet 2006;38:917-920. (Pubitemid 44141660)
190. Perl A, Nagy G, Koncz A, et al. Molecularmimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity 2008;41:287-297. (Pubitemid 351593859)
191. Magistrelli C, Samoilova E,Agarwal RK, et al. Polymorphic genotypes of theHRES-1humanendogenous retrovirus locus correlate with systemic lupus erythematosus and autoreactivity. Immunogenetics 1999;49:829-834. (Pubitemid 29381443)
192. Caza TN, Fernandez DR, Talaber G, et al. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis 2013.
193. Baixauli F,Martín-Cófreces NB,Morlino G, et al. Themitochondrial fission factor dynamin-related protein 1 modulates T-cell receptor signalling at the immune synapse. EMBO J 2011;30:1238-1250.
194. Nagy G,Ward J,Mosser DD, et al. Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem 2006;281:34574-34591. (Pubitemid 46036664)
195. Piliero P, Furie R. Functional asplenia in systemic lupus erythematosus. Semin Arthritis Rheum 1990;20:185-189.
196. Malleson P, Petty RE, Nadel H, Dimmick JE. Functional asplenia in childhood onset systemic lupus erythematosus. J Rheumatol 1988;15:1648-1652. (Pubitemid 19027784)
197. Kamdar N, Zanzi I, Kroop S, et al. Reversible functional asplenia in systemic lupus erythematosus. Clin NuclMed 1991;16:760-762.
198. Santilli D, Govoni M, Prandini N, et al. Autosplenectomy and antiphospholipid antibodies in systemic lupus erythematosus: a pathogenetic relationship? Semin Arthritis Rheum 2003;33: 125-133. (Pubitemid 37386206)
199. Chi CM, Kwok YY, Chak SL. Nocardiosis in systemic lupus erythematosus. Semin Arthritis Rheum 1997;26:675-683.
200. Cheng H, Huang D, Leu H. Disseminated nocardiosis with initial manifestation mimicking disease flare-up of systemic lupus erythematosus in an SLE patient [2]. AmJMed 2005;118:1297-1298. (Pubitemid 41566540)
201. DoddsEM,Echandi LV,Puente SI,Kaufman S. Subretinal abscessdue toNocardia farcinica resistant to trimethoprim- sulfamethoxazole in a patient with systemic lupus erythematosus. Ocul Immunol Inflamm 2006;14:249-251. (Pubitemid 44266805)
202. Hara H, Wakui F, Ochiai T. Disseminated nocardia farcinica infection in a patient with systemic lupus erythematosus. JMedMicrobiol 2011;60:847-850.
203. Mosel D,Harris L, Fisher E, et al. Disseminated Nocardia infection presenting as hemorrhagic pustules and ecthyma in a woman with systemic lupus erythematosus and antiphospholipid antibody syndrome. J Dermatol Case Rep 2013;7:52-55.
204. TamL-, Li EK,Wong S-, Szeto C-. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 2002;31:296-300. (Pubitemid 35252543)
205. Weng C, Lee N, Liu M, et al. A retrospective study of catastrophic invasive fungal infections in patients with systemic lupus erythematosus fromsouthern Taiwan. Lupus 2010;19:1204-1209.
206. Chen HS, Tsai WP, LeuHS, et al. Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology 2007;46:539-544. (Pubitemid 46344672)
207. Barber CE, Barnabe C. Another consequence of severe lupus: invasive fungal disease. J Rheumatol 2012;39:1772-1774.
208. Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine 1987;66:341-348. (Pubitemid 18020233)
209. Wasserman AM, Sarantopoulos GP, Khanna D. Fungal leukocytoclastic vasculitis as a presentation of systemic vasculitis in a patient with systemic lupus erythematosus. J Clin Rheumatol 2009;15:383-386.
210. Zimmermann III B, SpiegelM, Lally EV. Cryptococcal meningitis in systemic lupus erythematosus. Semin Arthritis Rheum 1992;22:18-24.
211. Pourrat O, Pitrou-Duterme E, Devoize J, Bonnefoy M. Cryptococcal meningitis occurring eight years before a diagnosis of lupus wasmade. JMycologieMedicale 2013.
212. Mok CC, Lau CS, Yuen KY. Cryptococcal meningitis presenting concurrently with systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:169-171. (Pubitemid 28241572)
213. Matsumura M, Kawamura R, Inoue R, et al. Concurrent presentation of cryptococcal meningoencephalitis and systemic lupus erythematosus. Mod Rheumatol 2011;21:305-308.
214. Mete B, Saltoglu N,VanliE, et al. Simultaneous cryptococcal and tuberculous meningitis in a patient with systemic lupus erythematosus. JMicrobiol Immunol Infect 2013.
215. Chen Y, Liao W,Wen H, et al. Primary cutaneous aspergillosis in a patient with systemic lupus erythematosus. Mycoses 2012;55:e42-e44.
216. Gonzalez-Crespo MR, Gomez-Reino JJ. Invasive aspergillosis in systemic lupus erythematosus. Semin Arthritis Rheum 1995;24:304-314.
217. Schattner A, Kagan A, Zimhony O. Aspergillus peritonitis in a lupus patient on chronic peritoneal dialysis. Rheumatol Int 2006;26:762-764. (Pubitemid 43725473)
218. Yegneswaran Prakash P, Pandit V, Rao SP. Fulminant antiphospholipid antibody syndrome complicated by Aspergillus tracheobronchitis. MedMycol Case Rep 2012;1:99-102.
219. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009;29:491-496.
220. Barber C,Gold WL, Fortin PR. Infections inthe lupus patient: perspectives onprevention. Curr Opin Rheumatol 2011;23:358-365.
221. Hansen KE, St. Clair EW. Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature. Semin Arthritis Rheum 1998;28:193-199. (Pubitemid 28563931)
222. Isotalo PA,McCarthy AE, Eidus L. Ovarian histoplasmosis in systemic lupus erythematosus. Pathology 2000;32:139-141. (Pubitemid 30249016)
223. Mok CC,Que TL, Tsui EYK,LamWY. Mucormycosis in systemic lupus erythematosus. SeminArthritis Rheum 2003;33:115-124. (Pubitemid 37386205)
224. Guarneri F, Guarneri B, VaccaroM, Guarneri C. The human Ku autoantigen shares amino acid sequence homology with fungal, but not bacterial and viral, proteins. Immunopharmacol Immunotoxicol 2011;33:329-333.
225. Reeves WH. Antibodies to the p70/p80 (Ku) antigens in systemic lupus erythematosus. Rheum Dis Clin North Am 1992;18:391-414.
226. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007;41:1992-2001. (Pubitemid 350230567)
227. Mora CS, Segami MI, Hidalgo JA. Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome. Semin Arthritis Rheum 2006;36: 135-143. (Pubitemid 44691883)
228. Rajadhyaksha A, Mehra S, Kawale J. Disseminated strongyloides in systemic lupus erythematosus and antiphospholipid antibody syndrome: a case report. Int J Rheum Dis 2012;15:e159-e161.
229. Hunter CJ, Petrosyan M, Asch M. Dissemination of strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: a case report. J Med Case Rep 2008:2. doi: 10. 1186/1752-1947-2-156
230. Sakkas LI, Boulbou M, Kyriakou D, et al. Immunological features of visceral leishmaniasis may mimic systemic lupus erythematosus. Clin Biochem 2008;41:65-68. (Pubitemid 350216833)
231. Tunccan OG, Tufan A, Telli G, et al. Visceral leishmaniasis mimicking autoimmune hepatitis, primary biliary cirrhosis, and systemic lupus erythematosus overlap. Korean J Parasitol 2012;50:133-136.
232. Zanini GM, de Moura Carvalho LJ, Brahimi K, et al. Sera of patientswith systemic lupus erythematosus react with plasmodial antigens and can inhibit the in vitro growth of Plasmodium falciparum. Autoimmunity 2009;42:545-552.
233. Willcocks LC, Carr EJ, Niederer HA, et al. A defunctioning polymorphism in FCGR2B is associated with protection againstmalaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci USA 2010;107:7881-7885.
234. Waisberg M, Tarasenko T, Vickers BK, et al. Genetic susceptibility to systemic lupus erythematosus protects against cerebralmalaria in mice. Proc Natl Acad Sci USA 2011;108:1122-1127.
235. Oates JC, Levesque MC, Hobbs MR, et al. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J Rheumatol 2003;30:60-67. (Pubitemid 36077773)
236. López-Nevot ḾA, Ramal L, Jiménez-Alonso J, Martín J. The inducible nitric oxide synthase promoter polymorphism does not confer susceptibility to systemic lupus erythematosus. Rheumatology 2003;42:113-116. (Pubitemid 36142012)
237. Chen M, Aosai F, Norose K, et al. Toxoplasma gondii infection inhibits the development of lupuslike syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice. Int Immunol 2004;16:937-946. (Pubitemid 38967175)
238. WilcoxMH,Powell RJ, Pugh SF, Balfour AH. Toxoplasmosis and systemic lupus erythematosus. Ann Rheum Dis 1990;49:254-257. (Pubitemid 20140752)
239. Amir DZ, Amar M, Groisman G, Weiner P. Toxoplasma infection in systemic lupus erythematosus mimicking lupus cerebritis. Mayo Clin Proc 1999;74:575-578. (Pubitemid 29264776)
240. Hasni SA. Role of helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol 2012;24:429-434.
241. Sawalha AH, Schmid WR, Binder SR, et al. Association between systemic lupus erythematosus and Helicobacter pylori seronegativity. J Rheumatol 2004;31:1546-1550 . (Pubitemid 39006635)
242. Müller A, Oertli M, Arnold ICH. Pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection. CellCommun Signal 2011:9. doi: 10. 1186/1478- 811X-9-25.
243. Zaccone P, Cooke A. Vaccine against autoimmune disease: can helminths or their products provide a therapy? Curr Opin Immunol 2013;25:418-423.
244. Strachan DP. Hay fever, hygiene, and household size. BrMed J 1989;299:1259-1260. (Pubitemid 19280051)
245. Dunne DW, Cooke A. A worm's eye view of the immune system: Consequences for evolution of human autoimmune disease. Nat Rev Immunol 2005;5:420-426. (Pubitemid 40685991)
246. van der Vlugt LEPM, Labuda LA,Ozir-Fazalalikhan A, et al. Schistosomes induce regulatory features in human and mouse CD1d hi B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. PLoS ONE 2012:7.
247. Khan AR, Fallon PG. Helminth therapies: translating the unknown unknowns to known knowns. Int J Parasitol 2013;43:293-299.
248. Bador KM, Intan S, Hussin S, Gafor AH. Serumprocalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 2012;21:1172-1177.
249. Koike T, Sueishi M, Funaki H, et al. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984;56:193-199. (Pubitemid 14161205)
250. WeissNL, Sadock VA, Sigal LH, et al. False positive seroreactivity to Borrelia burgdorferi in systemic lupus erythematosus: the value of immunoblot analysis. Lupus 1995;4:131-137.
251. Araujo FG, Barnett EV, Gentry LO, Remington JS. False-positive anti-Toxoplasma fluorescentantibody tests in patients with antinuclear antibodies. Appl Microbiol 1971;22:270-275.
252. Berkun Y, Zandman-Goddard G, Barzilai O, et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009;18:1129-1135.
253. Agmon-Levin N,Hughes G, Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 2012;21:118-120.
254. Verstraeten T,Descamps D,DavidM, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-6638.
255. Abu-Shakra M. Safety of vaccination of patients with systemic lupus erythematosus. Lupus 2009;18:1205-1208 .
256. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. ClinMicrobiol Rev 2003;16:357-364. (Pubitemid 36871311)
257. Holvast B, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006;65:913-918.
258. Crowe SR,Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011;63:2396-2406.
259. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann InternMed 1978;88:790-792.
260. Ambrosino DM,Molrine DC. Critical appraisal of immunization strategies for prevention of infection in the compromised host. Hematol Oncol Clin North Am1993;7:1027-1050. (Pubitemid 23294241)
261. Lipnick RN, Karsh J, Stahl NI, et al. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985;12:1118-1121. (Pubitemid 16166455)
262. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41:1828-1834. (Pubitemid 28465537)
263. Klippel JH, Karsh J, Stahl NI, et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979;22:1321-1325. (Pubitemid 10194569)
264. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 2013;22:238-244.
265. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports: Morbidity and mortalityweekly report. Recommendations and reports/Centers for Disease Control 2008;57:1-30; quiz CE2-304.
266. OxmanMN, LevinMJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl JMed 2005;352:2271-2284+2365. (Pubitemid 40740551)
267. Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax R in patients with hematologicmalignancy and hematopoietic cell transplant recipients. AmJ Hematol 2012;87:123-125.
268. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol 2013;11.
269. Soldevilla HF, Briones S, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012;21:158-161.
270. AytacMB, Kasapcopur O, AsianM, et al. Hepatitis B vaccination in juvenile systemic lupus erythematosus. Clin Exp Rheumatol 2011;29:882-886.
271. KurumaKAM, Borba EF, LopesMH, et al. Safety and efficacy of hepatitisBvaccine in systemic lupus erythematosus. Lupus 2007;16:350-354. (Pubitemid 47074837)
272. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-28.
273. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-4804.
274. Rolain J, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007;30:297-308. (Pubitemid 47364778)
275. Podrebarac TA, Jovaisas A, Karsh J. Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus. J Rheumatol 1996;23:199-200. (Pubitemid 26037219)
276. Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011;41:497-502.
277. Zysset MK, Montgomery MT, Redding SW, Dell'Italia LJ. Systemic lupus erythematosus: a consideration for antimicrobial prophylaxis. Oral Surg, OralMed, Oral Pathol 1987;64:30-34.